Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapyYoshio Nakamura, Naoya Yamazaki, Shigehisa Kitano et al.|Oncotarget|2016Cited by 160
Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study)Yasuhiro Nakamura, Naoya Yamazaki, Motoo Nomura et al.|ESMO Open|2021Cited by 57
A review of the AJCC melanoma staging system in the TNM classification (eighth edition)Dai Ogata, Naoya Yamazaki, Kenjiro Namikawa et al.|Japanese Journal of Clinical Oncology|2021Cited by 40
Real‐world efficacy and safety data of nivolumab and ipilimumab combination therapy in Japanese patients with advanced melanomaAkira Takahashi, Naoya Yamazaki, Kenjiro Namikawa et al.|The Journal of Dermatology|2020Cited by 24